Bionano Genomics, Inc. BNGO
1.23 USD +0.07 (+6.03%)
At closeNov 10, 2026, 7:28 PM EST
1.23 0.00 0.00%
After hours · Nov 10, 7:28 PM ET
1.16 Day range 1.35
1.06 52-week range 1.85
- YTD
- -19.61%
- 1 year
- -24.07%
News
seekingalpha.com Bionano Genomics, Inc. (BNGO) Q3 2026 Earnings Call Transcript Bionano Genomics, Inc. (BNGO) Q3 2026 Earnings Call Transcript
benzinga.com Bionano Genomics Q3 2026 Earnings Call Transcript Bionano Genomics (NASDAQ:BNGO) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Bionano Genomics Q3 EPS $(0.54) Misses $(0.51) Estimate, Sales $8.276M Miss $8.443M Estimate Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 8 percent. This is a 66.04 percent increase over losses of…
benzinga.com Bionano Genomics Affirms FY2026 Sales Guidance of $31.000M-$33.000M vs $32.474M Est Bionano Genomics (NASDAQ:BNGO) affirms FY2026 sales outlook from $31.000 million-$33.000 million to $31.000 million-$33.000 million vs $32.474 million estimate.- benzinga.com Bionano Genomics Q3 Sales $8.276M Miss $8.443M Estimate Bionano Genomics (NASDAQ:BNGO) reported quarterly sales of $8.276 million which missed the analyst consensus estimate of $8.443 million by 1.98 percent. This is a 12.34 percent increase over sales of…
globenewswire.com Bionano Reports Third Quarter 2026 Results and Provides a Business Update Conference call today, November 10, 2026, at 4:30 PM ET SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended…
globenewswire.com Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026 SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, November 10, 2026, at 4:30 p.m.…
globenewswire.com Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs),…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences…
benzinga.com Bionano Genomics Stock Surges Tuesday: What's Going On? Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…- benzinga.com Bionano Genomics Highlights Three New Independently Authored, Peer-Reviewed Publications Showing Clinical Utility Of OGM In High-Risk Hematologic Malignancies Bionano Genomics, Inc. (NASDAQ:BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk hematologic malignancies —…
globenewswire.com Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically…
benzinga.com Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that…
globenewswire.com Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs),…
globenewswire.com Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders,…
globenewswire.com Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global…
seekingalpha.com Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript- benzinga.com Bionano Genomics Raises FY2026 Sales Guidance from $30.000M-$33.000M to $31.000M-$33.000M vs $32.137M Est Bionano Genomics (NASDAQ:BNGO) raises FY2026 sales outlook from $30.000 million-$33.000 million to $31.000 million-$33.000 million vs $32.137 million estimate.
globenewswire.com Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026 SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m.…
globenewswire.com Bionano Announces Hiring of Chief Scientific Officer SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief…
globenewswire.com Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics…
globenewswire.com Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that…
zacks.com Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are…
globenewswire.com Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the…
globenewswire.com Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM)…
seekingalpha.com Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
zacks.com Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $1.15 per share a year ago.
benzinga.com Transcript: Bionano Genomics Q1 2026 Earnings Conference Call - benzinga.com Bionano Genomics Q1 EPS $(0.76) Beats $(0.95) Estimate, Sales $6.687M Beat $6.567M Estimate Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.95) by 20 percent. This is a 33.91 percent increase over losses of…
- benzinga.com Bionano Genomics Affirms FY2026 Sales Guidance of $30.000M-$33.000M vs $32.137M Est Bionano Genomics (NASDAQ:BNGO) affirms FY2026 sales outlook from $30.000 million-$33.000 million to $30.000 million-$33.000 million vs $32.137 million estimate.
globenewswire.com Bionano Reports First Quarter 2026 Results and Provides a Business Update SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with…
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com Bionano Genomics Files Shelf Registration To Offer Up To $400M In Common Stock, Preferred Stock, Debt, Warrants, And Units $400,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsFrom time to time, we may offer and sell up to an aggregate amount of $400,000,000 of any combination of the securities described in…- benzinga.com Bionano Genomics Appoints Chairman Al Luderer Interim President, CEO, Effective Immediately Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president and chief executive officer, effective May…
benzinga.com HC Wainwright & Co. Maintains Buy on Bionano Genomics, Lowers Price Target to $6 HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $7 to $6.
benzinga.com Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story Bionano Genomics stock soared on Monday as investors anticipated the company's Q4 earnings report.- benzinga.com Earnings Scheduled For March 23, 2026
benzinga.com Nasdaq Tumbles 2% Amid Rate-Hike Fears: Fear & Greed Index Remains In 'Extreme Fear' Zone The CNN Fear & Greed Index increased due to ongoing conflicts. U.S. stocks closed lower, with Nasdaq down 2%, while energy and financial sectors gained.
benzinga.com United Airlines, AGI And 3 Stocks To Watch Heading Into Monday US stock futures down, Caledonia Mining, United Airlines & Agi to report earnings, Cheetah Net & BioNano Genomics to release results.
benzinga.com Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Bionano Genomics, Inc. (BNGO) will release Q4 earnings on March 23. Analysts expect $1.40 loss per share on $7.85M revenue. Stock closed at $1.12.- benzinga.com Bionano Announces Two-Fold Increase in OGM Studies Presented At Annual Clinical Genetics Meeting Bionano Genomics participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing a two-fold…
benzinga.com Bionano Genomics Publishes Study On Application Of Optical Genome Mapping To Trace Genomic Alterations Introduced By Different Gene Editing Technologies Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of optical genome mapping (OGM) to…
benzinga.com Bionano Laboratories Gains 47% CMS Reimbursement Increase For OGM Blood-Cancer Test Code 81195 In 2026 Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced…
benzinga.com Baidu To Rally More Than 69%? Here Are 10 Top Analyst Forecasts For Monday - benzinga.com HC Wainwright & Co. Maintains Buy on Bionano Genomics, Lowers Price Target to $7 HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $11 to $7.
- benzinga.com Bionano Genomics Affirms FY2025 Sales Guidance of $26.000M-$30.000M vs $28.136M Est Bionano Genomics (NASDAQ:BNGO) affirms FY2025 sales outlook from $26.000 million-$30.000 million to $26.000 million-$30.000 million vs $28.136 million estimate.
- benzinga.com Bionano Genomics Q3 EPS $(1.59) Beats $(1.91) Estimate, Sales $7.367M Beat $6.871M Estimate Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1.91) by 16.75 percent. This is a 94.86 percent increase over losses of…
- benzinga.com Bionano Genomics Q3 Sales $7.367M Beat $6.871M Estimate Bionano Genomics (NASDAQ:BNGO) reported quarterly sales of $7.367 million which beat the analyst consensus estimate of $6.871 million by 7.22 percent. This is a 21.31 percent increase over sales of…